Table 2.
Antimicrobial agent | n | MICa (mg/dL) | Interpretation n (%) | ||||
---|---|---|---|---|---|---|---|
Range | 50 %b | 90 %b | Susceptible | Interpretive | Resistant | ||
Vancomycin | 29 | ≤2 | ≤2 | ≤2 | 29 (100) | 0 | 0 |
Imipenem | 29 | ≤0.5 to 4 | ≤0.5 | ≤0.5 | 29 (100) | 0 | 0 |
Gentamicin | 29 | ≤2 to 4 | ≤2 | 4 | 29 (100) | 0 | 0 |
Amikacin | 26 | ≤16 | ≤16 | ≤16 | 26 (100) | 0 | 0 |
Linezolid | 25 | ≤0.25 to 2 | 1 | 1 | 25 (100) | ||
Chloramphenicol | 22 | 2 to 4 | 4 | 4 | 22 (100) | 0 | 0 |
Rifampin | 15 | ≤1 | ≤1 | ≤1 | 15 (100) | 0 | 0 |
Levofloxacin | 29 | ≤0.12 to >16 | ≤0.5 | ≤0.5 | 26 (89.7) | 1 (3.4) | 2 (6.9) |
Clindamycin | 29 | <0.25 to ≥4 | 2 | 2 | 10 (34.5) | 18 (62.1) | 1 (3.4) |
Erythromycin | 29 | ≤0.25 to >16 | 0.5 | 1 | 18 (62.1) | 6 (20.7) | 2 (6.9) |
Cefazolin | 29 | ≤8 to ≥64 | ≤8 | 15 (51.7) | 6 (20.7) | 8 (27.6) | |
Daptomycin | 22 | ≤0.12 to 4 | 2 | 4 | 8 (36.4) | 12 (54.5)c | |
Cefotaxime | 22 | 4 to ≥64 | 16 | 32 | 2 (9.1) | 18 (81.8) | 2 (9.1) |
Ampicillin/sulbactam | 25 | ≤0.25 to >8 | 4 | >8 | 1 (4) | – | 24 (96) |
Ampicillin | 29 | 0.5 to >8 | >4 | >4 | 0 | – | 29 (100) |
Ceftazidime | 22 | 32 to >64 | >64 | >64 | 0 | 0 | 22 (100) |
aMinimum inhibitory concentration
bMIC at which 50 or 90 % of tested isolates are inhibited
cThis isolates were interpreted as “not susceptible” because the breakpoint was only set for susceptible